{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:35:38Z","timestamp":1767987338118,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001315","name":"Sid W. Richardson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001315","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017017","name":"Hamill Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017017","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jtos.2021.09.003","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T02:01:27Z","timestamp":1631844087000},"page":"162-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Combined therapy of ocular surface disease with plasma rich in growth factors and scleral contact lenses"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4068-5908","authenticated-orcid":false,"given":"Margaret","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sowmya","family":"Yennam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jake","family":"McMillin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1379-1561","authenticated-orcid":false,"given":"Hongan (Hannah)","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9779-879X","authenticated-orcid":false,"given":"Borja","family":"de la Sen-Corcuera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9755-2447","authenticated-orcid":false,"given":"Roxana","family":"Hemmati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Pflugfelder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.jtos.2021.09.003_bib1","doi-asserted-by":"crossref","first-page":"9271","DOI":"10.3390\/ijms21239271","article-title":"Defining dry eye from a clinical perspective","volume":"21","author":"Tsubota","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.jtos.2021.09.003_bib2","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jtos.2017.08.003","article-title":"TFOS DEWS II report executive summary. The ocular surface","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.jtos.2021.09.003_bib3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report. The ocular surface","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"issue":"11","key":"10.1016\/j.jtos.2021.09.003_bib4","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.ophtha.2017.07.022","article-title":"Update in current diagnostics and therapeutics of dry eye disease","volume":"124","author":"Thulasi","year":"2017","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.jtos.2021.09.003_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1444-0938.2002.tb03011.x","article-title":"What causes steroid cataracts? A review of steroid\u2010induced posterior subcapsular cataracts. Clinical and experimental optometry","volume":"85","author":"Jobling","year":"2002","journal-title":"Clin Exp Optom"},{"issue":"9","key":"10.1016\/j.jtos.2021.09.003_bib6","article-title":"Topical cyclosporine A therapy for dry eye syndrome","volume":"2019","author":"de Paiva C","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.jtos.2021.09.003_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.clae.2013.02.004","article-title":"Patient ocular conditions and clinical outcomes using a PROSE scleral device. Contact lens & anterior eye","volume":"36","author":"Dimit","year":"2013","journal-title":"Contact Lens Anterior Eye"},{"key":"10.1016\/j.jtos.2021.09.003_bib8","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.2147\/OPTH.S265701","article-title":"Human platelets and derived products in treating ocular surface diseases - a systematic review","volume":"14","author":"You","year":"2020","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"10.1016\/j.jtos.2021.09.003_bib9","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3109\/02713683.2015.1104362","article-title":"Plasma rich in growth factors for the treatment of ocular surface diseases","volume":"41","author":"Anitua","year":"2016","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jtos.2021.09.003_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.exer.2016.08.012","article-title":"PRGF exerts more potent proliferative and anti-inflammatory effects than autologous serum on a cell culture inflammatory model","volume":"151","author":"Anitua","year":"2016","journal-title":"Exp Eye Res"},{"issue":"8","key":"10.1016\/j.jtos.2021.09.003_bib11","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.1111\/aos.12710","article-title":"Autologous serum and plasma rich in growth factors in ophthalmology: Preclinical and clinical studies. Acta ophthalmologica (Oxford, England)","volume":"93","author":"Anitua","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jtos.2021.09.003_bib12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.exer.2015.02.016","article-title":"Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts","volume":"135","author":"Anitua","year":"2015","journal-title":"Exp Eye Res"},{"issue":"6","key":"10.1016\/j.jtos.2021.09.003_bib13","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2230.2011.04303.x","article-title":"Antibacterial effect of plasma rich in growth factors (PRGF\u00ae\u2010Endoret\u00ae) against staphylococcus aureus and staphylococcus epidermidis strains","volume":"37","author":"Anitua","year":"2012","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jtos.2021.09.003_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000487951","article-title":"Plasma rich in growth factors for the treatment of dry eye after LASIK surgery","volume":"60","author":"Sanchez-Avila","year":"2018","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.jtos.2021.09.003_bib15","first-page":"97","article-title":"Plasma rich in growth factors eye drops to treat secondary ocular surface disorders in patients with glaucoma. International medical case reports journal","volume":"11","author":"S\u00e1nchez-Avila","year":"2018","journal-title":"Int Med Case Rep J"},{"issue":"5","key":"10.1016\/j.jtos.2021.09.003_bib16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/jop.2016.0166","article-title":"The effect of immunologically safe plasma rich in growth factor eye drops in patients with sj\u00f6gren syndrome","volume":"33","author":"Sanchez-Avila","year":"2017","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2021.09.003_bib17","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2147\/OPTH.S252253","article-title":"Plasma rich in growth factors for the treatment of cicatrizing conjunctivitis","volume":"14","author":"de la Sen-Corcuera","year":"2020","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"10.1016\/j.jtos.2021.09.003_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000439280","article-title":"Autologous plasma rich in growth factors eyedrops in refractory cases of ocular surface disorders","volume":"55","author":"Merayo-Lloves","year":"2016","journal-title":"Ophthalmic Res"},{"issue":"8","key":"10.1016\/j.jtos.2021.09.003_bib19","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/ICO.0b013e3181a81820","article-title":"Plasma rich in growth factors as a therapeutic agent for persistent corneal epithelial defects","volume":"29","author":"L\u00f3pez-Plandolit","year":"2010","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.jtos.2021.09.003_bib20","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s10792-017-0582-7","article-title":"Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-endoret) eye-drops","volume":"38","author":"Sanchez-Avila","year":"2018","journal-title":"Int Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2021.09.003_bib21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S1542-0124(12)70053-8","article-title":"Development and validation of a short global dry eye symptom index. The ocular surface","volume":"5","author":"Schaumberg","year":"2007","journal-title":"Ocul Surf"},{"issue":"7","key":"10.1016\/j.jtos.2021.09.003_bib22","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.ophtha.2015.02.037","article-title":"Comparison of two questionnaires for dry eye symptom assessment: the ocular surface disease index and the symptom assessment in dry eye","volume":"122","author":"Amparo","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2021.09.003_bib23","first-page":"631","article-title":"Thermal and chemical burns","volume":"85","author":"Roper-Hall","year":"1965","journal-title":"Trans Ophthalmol Soc U K"},{"issue":"10","key":"10.1016\/j.jtos.2021.09.003_bib24","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1097\/ICO.0b013e31829f7088","article-title":"Biological stability of plasma rich in growth factors eye drops after storage of 3 months","volume":"32","author":"Anitua","year":"2013","journal-title":"Cornea"},{"issue":"7","key":"10.1016\/j.jtos.2021.09.003_bib25","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/bjo.87.7.834","article-title":"Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases","volume":"87","author":"Bourcier","year":"2003","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.jtos.2021.09.003_bib26","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/ICO.0b013e3182910036","article-title":"Contamination risk of 100% autologous serum eye drops in management of ocular surface diseases","volume":"32","author":"Thanathanee","year":"2013","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.jtos.2021.09.003_bib27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/ICO.0000000000002519","article-title":"Short- and long-term stability of plasma rich in growth factors eye drops","volume":"40","author":"Anitua","year":"2021","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2021.09.003_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.exer.2013.07.007","article-title":"Plasma rich in growth factors (PRGF-endoret) stimulates corneal wound healing and reduces haze formation after PRK surgery","volume":"115","author":"Anitua","year":"2013","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jtos.2021.09.003_bib29","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ajoc.2018.02.010","article-title":"Improvement of chronic corneal opacity in ocular surface disease with prosthetic replacement of the ocular surface ecosystem (PROSE) treatment. American journal of ophthalmology case reports","volume":"10","author":"Cressey","year":"2018","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"2","key":"10.1016\/j.jtos.2021.09.003_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40135-013-0009-1","article-title":"Dry eye disease: impact on quality of life and vision","volume":"1","author":"Uchino","year":"2013","journal-title":"Curr Ophthalmol Rep"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012421001026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012421001026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:43:40Z","timestamp":1761540220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012421001026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":30,"alternative-id":["S1542012421001026"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2021.09.003","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined therapy of ocular surface disease with plasma rich in growth factors and scleral contact lenses","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2021.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}